697 related articles for article (PubMed ID: 28478488)
1. Epidemiology, management and outcomes of Graves' disease-real life data.
Hussain YS; Hookham JC; Allahabadia A; Balasubramanian SP
Endocrine; 2017 Jun; 56(3):568-578. PubMed ID: 28478488
[TBL] [Abstract][Full Text] [Related]
2. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
[No Abstract] [Full Text] [Related]
3. Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.
Fung MHM; Lang BHH
Eur Radiol; 2023 Sep; 33(9):6534-6544. PubMed ID: 37036479
[TBL] [Abstract][Full Text] [Related]
4. Graves' disease in children.
Léger J; Oliver I; Rodrigue D; Lambert AS; Coutant R
Ann Endocrinol (Paris); 2018 Dec; 79(6):647-655. PubMed ID: 30180972
[TBL] [Abstract][Full Text] [Related]
5. Graves' disease in children: long-term outcomes of medical therapy.
Rabon S; Burton AM; White PC
Clin Endocrinol (Oxf); 2016 Oct; 85(4):632-5. PubMed ID: 27169644
[TBL] [Abstract][Full Text] [Related]
6. Outcomes analysis of radioactive iodine and total thyroidectomy for pediatric Graves' disease.
Cohen RZ; Felner EI; Heiss KF; Wyly JB; Muir AB
J Pediatr Endocrinol Metab; 2016 Mar; 29(3):319-25. PubMed ID: 26656610
[TBL] [Abstract][Full Text] [Related]
7. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
Bogazzi F; Giovannetti C; Fessehatsion R; Tanda ML; Campomori A; Compri E; Rossi G; Ceccarelli C; Vitti P; Pinchera A; Bartalena L; Martino E
J Clin Endocrinol Metab; 2010 Jan; 95(1):201-8. PubMed ID: 19906789
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study.
Sundaresh V; Brito JP; Thapa P; Bahn RS; Stan MN
Thyroid; 2017 Apr; 27(4):497-505. PubMed ID: 28049375
[TBL] [Abstract][Full Text] [Related]
9. Variation in the use of definitive treatment options in the management of Graves' disease: a UK clinician survey.
Hookham J; Collins EE; Allahabadia A; Balasubramanian SP
Postgrad Med J; 2017 Apr; 93(1098):198-204. PubMed ID: 27531964
[TBL] [Abstract][Full Text] [Related]
10. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group.
Törring O; Tallstedt L; Wallin G; Lundell G; Ljunggren JG; Taube A; Sääf M; Hamberger B
J Clin Endocrinol Metab; 1996 Aug; 81(8):2986-93. PubMed ID: 8768863
[TBL] [Abstract][Full Text] [Related]
11. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial.
Watt T; Cramon P; Bjorner JB; Bonnema SJ; Feldt-Rasmussen U; Gluud C; Gram J; Hansen JL; Hegedüs L; Knudsen N; Bach-Mortensen P; Nolsøe R; Nygaard B; Pociot F; Skoog M; Winkel P; Rasmussen AK
Trials; 2013 Apr; 14():119. PubMed ID: 23782950
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.
Jin M; Jang A; Kim CA; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36826832
[TBL] [Abstract][Full Text] [Related]
13. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.
Okosieme OE; Taylor PN; Evans C; Thayer D; Chai A; Khan I; Draman MS; Tennant B; Geen J; Sayers A; French R; Lazarus JH; Premawardhana LD; Dayan CM
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):278-287. PubMed ID: 30827829
[TBL] [Abstract][Full Text] [Related]
14. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
[TBL] [Abstract][Full Text] [Related]
15. Pediatric Graves' disease: decisions regarding therapy.
Okawa ER; Grant FD; Smith JR
Curr Opin Pediatr; 2015 Aug; 27(4):442-7. PubMed ID: 26087421
[TBL] [Abstract][Full Text] [Related]
16. Thyroid nodules in Graves' disease: classification, characterization, and response to treatment.
Carnell NE; Valente WA
Thyroid; 1998 Aug; 8(8):647-52. PubMed ID: 9737358
[TBL] [Abstract][Full Text] [Related]
17. Thyroid nodules in Graves' disease: classification, characterization, and response to treatment.
Carnell NE; Valente WA
Thyroid; 1998 Jul; 8(7):571-6. PubMed ID: 9709909
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves' disease.
Donovan PJ; McLeod DS; Little R; Gordon L
Eur J Endocrinol; 2016 Dec; 175(6):595-603. PubMed ID: 27634939
[TBL] [Abstract][Full Text] [Related]
19. Management of recurrent hyperthyroidism in patients with Graves' disease treated by subtotal thyroidectomy.
Sugino K; Mimura T; Ozaki O; Iwasaki H; Wada N; Matsumoto A; Ito K
J Endocrinol Invest; 1995 Jun; 18(6):415-9. PubMed ID: 7594234
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
